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Abstract

As part of analgosedative treatment modalities after delivery (e.g.
caesarean related pain, birth related trauma, pre-existing pain syndromes),
mothers are treated with different analgosedatives that may also affect the
nursing infant. This review aims to summarize the available knowledge on
commonly prescribed analgosedatives (opioids, intravenous and inhalational
anesthetics, benzodiazepines, non-opioid analgesics, and local anesthetics)
during breastfeeding.
We propose that the use of systemic non-opioid analgesics, local
anesthetics, inhalational or intravenous anesthetics is safe when mothers
are nursing. When systemic opioids are used, we recommend pediatricians
to consider clinical monitoring of the infant for sedation. The duration of
maternal exposure (> 4 days) and the presence of maternal signs of somnolence
are hereby of additional relevance. We encourage research groups to report
on their specific observations and expertise in order to further validate the
current practices and guidance.
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Introduction

Most drugs are not extensively evaluated during
pregnancy or postpartum, including the setting of
breastfeeding [1-3]. This is to a large extent similar
to the off-label and unlicensed pharmacotherapy
in neonates and children. Consequently, the label
commonly mentions a default setting that “the
drug has not been studied during pregnancy or
breastfeeding”. Despite this, nursing women often
need pharmacological treatment for a range of
conditions. The ultimate goals of maternal drug
use during breastfeeding are dual. First, this should
provide effective and safe therapy for the maternal
condition(s) (e.g. postpartum maternal analgesia,
maternal co-morbidities, pregnancy related diseases). Simultaneously, we also aim to assure the
safety for the nursing infant from (relevant) adverse
events related to the maternal treatment [1-3]. Only
very rarely, these goals overlap (e.g. maternal
galactagogues intake to induce milk production,
like metoclopramide or domperidone) [4].

In essence, exposure of a nursing mother to
any dose of drug (maternal dose, Dm) will result
in – be it very limited – transfer of the drug into
the human milk (estimated infant dose, Di).
However, concentrations reached in the human milk
are usually quite low and oral bioavailability in the
infant should also be considered before any relevant
pharmacological exposure (relative infant dose,
RID = Dm/Di * absorption) and effect in the infant
needs to be anticipated (Fig. 1). The difference in
drug concentration in the infant’s plasma (a vs b) can
be explained by the presence (a) or absence (b) of
“initial loading related to fetal exposure to the same
compound before delivery” [5, 6]. Age also matters,
since the newborn seems to be more vulnerable to
adverse effects when compared to infants and refers
to the age-related changes in pharmacokinetics
or -dynamics [7]. In essence, most drugs appear
in mother’s milk, but the final concentration time
profiles in the infant depend on the concentration
in the milk, the bio-availability, clearance capacity
and the initial concentration (fetal + neonatal or only
neonatal exposure). Finally, accumulation relates to
the duration of exposure and the initial concentration
in the newborn. In the setting of continuation
of treatment of the mother from pregnancy to
postpartum, the fetus will likely already be exposed
to the maternal drugs, and the newborn will already

Figure 1. Maternal-infant pharmacokinetics in the setting of exposure through breastfeeding. The difference in drug
concentration in the infant’s plasma (a vs b) can be explained by the presence (a) or absence (b) of “initial loading related
to fetal exposure to the same compound before delivery” [5, 6].
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have an initial concentration of this compound at
birth. The subsequent concentration will depend
on the amount of exposure, the clearance capacity
and the distribution volume characteristics (e.g.
postnatal weight evolution) [5-7].
Despite the fact that lactating women are regular
users of medications and that women are often
advised to discontinue or stop nursing while taking
the drug, there are only a limited number of drugs
that have been identified as potentially harmful to the
newborn [5, 6]. Using a prospective study design, Ito
et al. documented in a cohort of 838 nursing infants
with mothers taking medications that the incidence
of adverse reactions was 11.2% (94/838) [8]. All
these events were classified as minor reactions, not
necessitating medical attention. Antibiotics (19.3%),
antihistamines (9.4%), sedatives, antidepressants
or anti-epileptics (7.1%), but also analgesics,
including narcotics (11.2%) were most commonly
associated with adverse reactions. The reported
adverse reactions were diarrhea (antibiotics),
drowsiness (analgesics, sedatives, antidepressants,
antiepileptics) or irritability (antihistamines) [8].
The incidence, the type of reactions and compounds
associated are in line with the systematic literature
review performed by Anderson et al. [5]. Based on
the evaluation of 100 published case reports, none
were considered to be “definite” using a standard
ranking scale, 47% were “probable”, 53% were
“possible”. However, drugs with central nervous
system activity accounted for about 50% of the
events [5].
These data suggest that breastfeeding rarely
needs to be discouraged or discontinued when a
mother needs drug therapy, but some cautiousness
about analgosedatives may be warranted [5, 6, 8].
As part of analgosedative treatment modalities after
delivery (e.g. caesarean related pain, birth related
trauma, pre-existing pain syndromes), mothers
are exposed to different analgosedatives that may
affect the nursing infant. This review aims to
summarize the available knowledge on commonly
prescribed analgosedatives (opioids, intravenous
and inhalational anesthetics, benzodiazepines, nonopioid analgesics, and local anesthetics) during
breastfeeding.
Compound specific observations

Opioids
The rate of breastfeeding has increased again
steadily in the developed world [9, 10]. During
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this time, opioid use in the general population
steadily increased as well. This means that the
clinical experience with maternal opioids is still
fairly limited with emerging data on (side)effects
with codeine, oxycodone, methadone and tramadol
during nursing [6, 11]. Opioid absorption after
oral ingestion in neonates should be anticipated,
while the extent of exposure through mother’s
milk will depend on maternal ingestion (dose)
and metabolism. Neonatal clearance relates to the
neonate’s metabolic or renal elimination, and will
be limited [7]. Such a setting has the potential to
result in unanticipated side effects in individual
cases.
A pivotal case report in 2006 of Koren et al.
on codeine related poisoning in a newborn through
breastfeeding reactivated the clinical research on
maternal-infant opioid pharmacokinetics [12]. A
pharmacogenetic link between maternal ultrafast
metabolizer status for cytochrome p450 (CYP)
2D6 was documented, since this results in higher
and faster conversion of codeine to morphine
[12]. More recently, the same group documented
that a combination of different maternal genetic
polymorphisms (i.e. CYP 2D6 and P-glycoprotein
polymorphisms) predicted 87% of the infant and
maternal central nervous system depression cases
with a sensitivity of 80% and a specificity of 87%
in a cohort of 111 breastfeeding mother-infant
pairs [13].
The incidence of central nervous system
depression in breastfed neonates following maternal
exposure to oxycodone, codeine or paracetamol
was retrospectively compared in 533 mother-infant
pairs. Lam et al. hereby clearly showed that there
was a 20.1% rate of depression in infants of nursing
mothers on oxycodone, as compared with 16.7%
and 0.5% when treated with codeine or paracetamol
[14]. Methadone is somewhat an outlier, since
commonly used in a setting of maternal opioid
addiction. Consequently, these neonates are already
exposed to methadone in fetal life. Methadone is
excreted into human milk (2-3% of weight-adjusted
maternal dose), and there are data that suggest that
these infants benefit from breastfeeding (blunted
opioid withdrawal syndrome), hereby confirming
an exposure/effect relation. Breastfed babies less
commonly display neonatal abstinence syndrome
and, if needed, the cumulative dose of methadone
is lower and the length of hospital stay is shorter
[6]. Finally, using a sparse sampling study design
to assess transfer of tramadol and O-desmethyl
tramadol into transitional breast milk, the relative
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infant dose of 2-3% remained very limited. Based
on these observations, the authors concluded that
short-term maternal use of tramadol is compatible
with breastfeeding [15].
There are also some additional clinical useful
observations on maternal codeine and oxycodone
exposure for the pediatrician. First, there is high
concordance between maternal and neonatal
somnolence. When the mother exhibits somnolence,
the baby should be examined by a pediatrician.
Secondly, severe somnolence commonly emerged
after 4 days of use, when milk output increases,
exposure increases and is prolonged. Therefore, any
maternal need for opioids for more than 4 days after
delivery warrants additional evaluation [16-18].
Obviously, there are major differences when
opioids are administered by either systemic (oral,
intravenous, transcutaneous) routes compared to
loco-regional anesthesia. To illustrate this, we refer
to the estimations of infant exposure in a setting
of patient (maternal) controlled epidural pethidine
administration [19]. The combined absolute infant
dose of pethidine and norpethidine received via
milk was 1.8% of the neonatal therapeutic dose
and the combined relative infant dose was below
the 10% recommended safety level. Based on these
data, the authors concluded that breastfed infants
are at low risk of relevant drug exposure in the
setting of patient-controlled epidural pethidine [19].
The interaction between locoregional analgesia and
breastfeeding outcome goes beyond drug exposure
through breastfeeding, and we refer the interested
reader to some reviews on this topic [20, 21].
Intravenous and inhalational anesthetics
Although the number of observations is limited,
excretion of propofol in human milk does not equal
infant exposure (Fig. 1) [22, 23]. This is because
enteral absorption is the rate limiting factor. The
same holds true for inhalational agents in postpartum,
but buccal etomidate resorption has been observed.
Obviously, this rationale only applies when these
compounds are administered after delivery, since
when administered during labor or before delivery,
placental passage may result in fetal accumulation
and subsequent effects [22].
Benzodiazepines
Lorazepam, midazolam or diazepam are
commonly administered as anxiolytic. These
compounds and some of their metabolites can be
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retrieved in human milk but concentrations remain
very limited [22-24]. In 24 hours of human milk
collection after a single dose, only 0.005% of the
maternal midazolam dose was retrieved. Taking
the subsequent oral bio-availability (50-60%) into
account, it is very reasonable to assume that the
exposure will be limited when administered after
delivery. In contrast, plasma diazepam and its active
metabolite (desmethyldiazepam) could be measured
up to 7-10 days of postnatal age in neonatal plasma
samples after administration to the mother before
delivery [24].
Non-opioid analgesics
Human milk and plasma paracetamol levels
were monitored in 3 lactating women after ingestion
of 500 mg dose of paracetamol in the postpartum
period. Paracetamol concentrations remained lower
in human milk (milk/plasma ratio of 0.76). Since
less than 0.1% of the maternal dose would be present
in 100 ml milk, nursing should not be discontinued
following maternal paracetamol exposure [25].
Similarly, ibuprofen in human milk and serum was
quantified in 12 patients who had ingested one 400
mg tablet of ibuprofen every 6 hours over a 24 hour
period immediately following delivery (relief postcaesarean pain). Ibuprofen could not be quantified
in human milk [26]. Based on the lower limit of
quantification (1 µg/ml), less than 1 mg of ibuprofen
per day is excreted in breast milk. Similar findings
have been described for ketorolac [27]. Even if
these compounds result in exposure, the extent will
remain limited and much lower than that clinical
registered dosing for analgesia or temperature
reduction [28].
Local anesthetics
Local anesthetics (including lidocaine, ropivacaine, and bupivacaine) are commonly administered as part of regional anesthetic techniques (e.g.
regional pain block, epidural) and data are mainly
available in mothers during labor or for anesthesia
[29]. Data on excretion of lidocaine and bupivacaine
in human milk have been reported. To illustrate
this, we refer to a paper of Giuliani et al. [30]. The
authors quantified lidocaine and its metabolite
(monoethyl-glycinexylidide, MEGX) disposition in
7 nursing mothers (23-39 years, 3.6 to 7.2 ml 2%
lidocaine without adrenaline, dental care). Based
on these observations, the daily infant exposure to
lidocaine and MEGX were 73.41 ± 38.94 µg/L/day
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and 66.1 ± 28.5 µg/L/day. Moreover, absorption
following oral ingestion is limited. Based on the
available evidence, the exposure is limited with
minor statistical significant, but clinical irrelevant
effects.
Discussion

There is an increase in breastfeeding, supported
by – among others – the Baby Friendly Hospital
initiative. Consequently, women also want to
breastfeed shortly following analgosedation [9, 10,
23]. In general, the short-term use of these drugs
already limits the risks of these effects, while
prolonged exposure should increase our vigilance.
Based on the observations retrieved in literature, the use of systemic non-opioid analgesics,
local anesthetics, and inhalational or intravenous
anesthetics seems safe for nursing mothers.
When systemic opioids are used, we recommend
pediatricians to consider some clinical monitoring
with specific emphasis on the duration of
exposure (4 days pivotal) and the presence of
any maternal sign (somnolence) [16]. Finally, the
use of benzodiazepines should be limited with
preference to those with shorter half-life. Under
these circumstances, the most appropriate advice
to a nursing mother undergoing anesthesia is that
she may reinitiate breastfeeding when she feels
sufficiently alert to do so.
Obviously, the knowledge on clinical pharmacology during breastfeeding evolves rapidly and
has become a field of active clinical research. This
means that updated, reliable information should
be easy accessible. Besides textbooks, LactMed is
a free online database with information on drugs
and lactation as one of the newest additions to the
National Library of Medicine’s TOXNET system
[31]. Similarly, the Motherisk program also has an
updated and useful website that can be searched,
and is open for advice [32]. We encourage research
groups to report on their specific observations and
expertise in order to further validate the current
practices.
Neonatal abstinence syndrome (NAS) following
prolonged maternal exposure to opioids is a separate
setting that warrants a tailored, specific approach
[33]. As part of such a tailored approach, there are
data that suggest that breastfeeding reduces the
incidence and duration of NAS [33-36]. Based on
a pooled dataset of 400 neonates (218 breastfed,
54.5%), there is a significant reduction in NAS (54%
vs 77%, number needed to treat 5-6). The same trends
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are observed when the duration of opioid treatment
(18 to 23 days) or the length of hospital stay (4 to 10
days) are considered [34-36]. Another benefit with
this approach is that administering methadone to
the neonate and young infant through breastfeeding
results in much more gradual exposure to this drug
and prevent inadvertent dosing. The major limitation
of the above mentioned observational studies is
bias. All studies reported that breastfed neonates
required less pharmacological interventions and
had shorter hospital stays. However, these effects
may be due to confounding (i.e. breastfeeding is just
a “marker”) factors. Among others, these could be
better adherence, less psychological co-morbidity,
or differences in staff attitudes towards nursing
women [37].
Conclusions

In conclusion, the use of systemic non-opioid
analgesics, local anesthetics, inhalational or
intravenous anesthetics seems safe when mothers
are nursing. When systemic opioids are used, we
recommend pediatricians to consider some clinical
monitoring with specific emphasis on the duration
of exposure and the presence of any maternal sign
(somnolence). We encourage research groups to
report on their specific observations and expertise
in order to further validate the current practices and
guidance.
Acknowledgements
The clinical research of Karel Allegaert is supported by the Fund for
Scientific Research, Flanders (Fundamental Clinical Investigatorship
1800214N). Johannes N. van den Anker is supported by NIH grants
(R01HD048689, K24DA027992, U54HD071601) and FP7 grants
TINN (223614), TINN2 (260908) and GRIP (261060).

Declaration of interest
The Authors declare that there is no conflict of interest.

References
1.

Sachs HC, Committee on drugs. The transfer of drugs and
therapeutics into human breast milk: an update on selected topics.
Pediatrics. 2013;132(3):e796-809.

2.

Ramoz LL, Patel-Shori NM. Recent changes in pregnancy and
lactation labeling: retirement of risk categories. Pharmacotherapy.
2014;34(4):389-95.

3.

Thomas SH, Yates LM. Prescribing without evidence – pregnancy.
Br J Clin Pharmacol. 2012;74(4):691-7.

5/6

www.jpnim.com Open Access

4.

Journal of Pediatric and Neonatal Individualized Medicine • vol. 4 • n. 1 • 2015

Forinash AB, Yancey AM, Barnes KN, Myles TD. The use of
galactogogues in the breastfeeding mother. Ann Pharmacother.
2012;46(10):1392-404.

5.

6.

7.

Ternullo SR, Thevenet-Morrison KN, Childs CK, Lawrence RA.

reactions in breastfed infants: less than imagined. Clin Pediatr.

Labor epidural anesthesia, obstetric factors and breastfeeding

2003;42(4):325-40.

cessation. Matern Child Health J. 2013;17(4):689-98.

Berlin CM Jr, van den Anker JN. Safety during breastfeeding:

22. Nitsun M, Szokol JW, Saleh HJ, Murphy GS, Vender JS, Luong L,

drugs, foods, environmental chemicals, and maternal infections.

Raikoff K, Avram MJ. Pharmacokinetics of midazolam, propofol,

Semin Fetal Neonat Med. 2013;18(1):13-8.

and fentanyl transfer to human breast milk. Clin Pharmacol Ther.

Allegaert K, Langhendries JP, van den Anker JN. Educational
2013;172(4):429-35.
Ito S, Blajchman A, Stephenson M, Eliopoloulos C, Koren

2006;79(6):549-57.
23. Dalal PG, Bosak J, Berlin C. Safety of the breast-feeding infant
after maternal anesthesia. Pediatr Anesth. 2014;24(4):359-71.
24. Cole AP, Hailey DM. Diazepam and active metabolite in breast milk

G. Prospective follow up of adverse reactions in breast-fed

and their transfer to the neonate. Arch Dis Child. 1975;50(9):741-2.

infants exposed to maternal medication. Am J Obstet Gynecol.

25. Bitzén PO, Gustafsson B, Jostell KG, Melander A, Wahlin-Boll

1993;168(5):1393-9.
9.

Nurs. 2012;41(3):339-46.
21. Dozier AM, Howard CR, Brownell EA, Wissler RN, Glantz JCn

Anderson PO, Pochop SL, Manoguerra AS. Adverse drug

paper: do we need neonatal clinical pharmacologists? Eur J Pediatr.
8.

postcesarean pain and breastfeeding. J Obstet Gynecol Neonatal

Saadeh RJ. The Baby-Friendly Hospital Initiative 20 years on:

E. Excretion of paracetamol in human breast milk. Eur J Clin
Pharmacol. 1981;20(2):123-5.

facts, progress, and the way forward. J Hum Lact. 2012;28(3):272-5.

26. Townsend RJ, Benedetti TJ, Erickson SH, Cenqiz C, Gillespie WR,

10. Hellwig JP. Encouraging breastfeeding: initiative to help hospitals

Gschwend J, Albert KS. Excretion of ibuprofen into breast milk.

become baby-friendly. Nurs Womens Health. 2012;16(1):79.
11. Hendrickson RG, McKeown NJ. Is maternal opioid use hazardous
to breast-fed infants? Clin Toxicol. 2012;50(1):1-14.
12. Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ.
Pharmacogenetics of morphine poisoning in a breastfed neonate of
a codeine-prescribed mother. Lancet. 2006;368(9536):704.
13. Sistonen J, Madadi P, Ros CJ, Yazdanpanah M, Lee JW, Landsmeer

Am J Obstet Gynecol. 1984;149(2):184-6.
27. Wischnik A, Manth SM, Lloyd J, Bullingham R, Thompson JS.
The excretion of ketorolac tromethamine into breast milk after
multiple oral dosing. Eur J Clin Pharmacol. 1989;36(5):521-4.
28. Bloor M, Paech M. Nonsteroidal anti-inflammatory drugs
during pregnancy and the initiation of lactation. Anesth Analg.
2013;116(5):1063-75.

ML, Nauta M, Carleton BC, Koren G, Hayden MR. Prediction

29. Ortega D, Viviand X, Lorec AM, Gamerre M, Martin C, Bruguerolle

of codeine toxicity in infants and their mothers using a novel

B. Excretion of lidocaine and bupivacaine in breast milk following

combination of maternal genetic markers. Clin Pharmacol Ther.

epidural anesthesia for cesarean delivery. Acta Anaesthesiol Scand.

2012;91(4):692-9.

1999;43(4):394-7.

14. Lam J, Kelly L, Ciszkowski C, Landsmeer ML, Nauta M, Carleton

30. Giuliani M, Grossi GB, Pileri M, Lajolo C, Casparrini G. Could

BC, Hayden MR, Madadi P, Koren G. Central nervous system

local anesthesia while breast-feeding be harmful to infants? J

depression of neonates breastfed by mothers receiving oxycodone

Pediatr Gastroenterol Nutr. 2001;32(2):142-4.

for postpartum analgesia. J Pediatr. 2012;160(1):33-7.e2.
15. Salman S, Sy SK, Ilett KF, Page-Sharp M, Paech MJ. Population

31. US National Library of Medicine. http://toxnet.nlm.nih.gov/
newtoxnet/lactmed.htm, last access: 01 March 2015.

pharmacokinetic modeling of tramadol and its O-desmethyl

32. http://www.motherisk.org, last access: 01 March 2015.

metabolite in plasma and breast milk. Eur J Clin Pharmacol.

33. Allegaert K, van den Anker JN. Neonatal abstinence syndrome: on

2011;67(9):899-908.
16. Van den Anker JN. Is it safe to use opioids for obstetric pain while
breastfeeding? J Pediatr. 2012;160(1):4-6.

the evidence to add breastfeeding to any clinical pathway. Pediatr
Crit Care Med. 2014;15(6):579-80.
34. Abdel-Latif ME, Pinner J, Clews S, Cooke F, Lui K, Oei J. Effects

17. Timm NL. Maternal use of oxycodone resulting in opioid

of breast milk on the severity and outcome of neonatal abstinence

intoxication in her breastfed neonate. J Pediatr. 2013;162(2):

syndrome among infants of drug-dependent mothers. Pediatrics.

421-2.
18. Rivers CM, Olsen D, Nelson LS. Breastfeeding and oxycodone.
J Pediatr. 2012;161(1):174.

2006;117(6):e1163.
35. Wachman EM, Hayes MJ, Brown MS, Paul J, Harvey-Wilkes
K, Teerin N, Huggins GS, Aranda JV, Davis JM. Association

19. Al-Tamimi Y, Ilett KF, Paech MJ, O’Halloran SJ, Hartmann

of OPRM1 and COMT single-nucleotide polymorphisms with

PE. Estimation of infant dose and a exposure to pethidine and

hospital length of stay and treatment of neonatal abstinence

norpethidine via breast milk following patient-controlled epidural

syndrome. JAMA. 2013;309(16):1821-7.

pethidine for analgesia post caesarean delivery. Int J Obstet Anesth.
2011;20(2):128-34.
20. Woods AB, Crist B, Kowalewski S, Carroll J, Warren J,

6/6

36. Welle-Strand GK, Skurtveit S, Jansson LM, Bakstad B, Bjarko L,
Ravndal E. Breastfeeding reduces the need for withdrawal treatment
in opioid-exposed infants. Acta Paediatr. 2013;102(11):1060-6.

Robertson J. A cross-sectional analysis of the effect of patient-

37. Lefevere J, Allegaert K. Is breastfeeding useful in the management

controlled epidural analgesia versus patient controlled analgesia for

of neonatal abstinence syndrome? Arch Dis Child. 2015;100(4):414-5.

Allegaert • van den Anker

